Michael Leapman, MD, MHS, presented “Utilization and Disparity in Prostate Cancer Risk Assessment Tools” at the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Leapman, Michael. “Utilization and Disparity in Prostate Cancer Risk Assessment Tools” October 2024. Accessed Mar 2025. https://grandroundsinurology.com/utilization-and-disparity-in-prostate-cancer-risk-assessment-tools/
Utilization and Disparity in Prostate Cancer Risk Assessment Tools – Summary
Michael Leapman, MD, MHS, delivers a 9-minute presentation on disparities and utilization patterns of prostate cancer risk assessment tools. He underscores the significant advancements in diagnostic modalities, including biomarkers, imaging techniques like prostate MRI and PSMA PET, and gene expression tests. He notes, however, marked regional and sociodemographic disparities in patients, with Black, Hispanic, and Asian patients significantly less likely to access advanced diagnostics compared to white patients.
Dr. Leman emphasizes addressing these disparities to ensure equitable access to life-saving technologies. His talk provides essential insights into the challenges and opportunities in closing gaps in prostate cancer diagnostics, ensuring fair and comprehensive care for all populations.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Dr. Leapman is an Assistant Professor of Urology at the Yale School of Medicine in New Haven, Connecticut. He was drawn to the field of urology by the opportunity to care for patients with urologic cancers. Dr. Leapman graduated from Cornell University, where he majored in Neurobiology and Behavior, and received his medical degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York City. Subsequently, he completed a two-year Urologic Oncology Fellowship at the University of California, San Francisco (UCSF), accredited by the Society of Urologic Oncology. He was recruited to join the faculty at the Yale University School of Medicine Smilow Cancer Center in 2016. He specializes in urologic oncology, and has a joint appointment at the West Haven Veterans Affairs Medical Center. His clinical interests include low-risk prostate cancer, active surveillance, nerve-sparing robotic prostatectomy, focal therapy, high-risk disease, and pelvic lymph node dissection.
